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Abstract 
Introduction During prostatic carcinogenesis, DNA 
hypermethylation occurs, thus representing a promising biomarker for the 
early detection of this malignancy. In our study, we aim to determine the 
usefulness of a molecular and multigene test for prostate cancer. However, 
this is based on the quantitative methylation-specific polymerase chain 
reaction (qMSP) of three genes from voided urine specimens by noninvasive 
methods. 
Materials and Methods In this study, the voided urine specimens were 
collected from 89 patients with prostate cancer and 69 controls. Genomic 
DNA was isolated and subjected to bisulfite modification. Consequently, we 
tested the methylation status of genomic DNA of three genes, namely: 
GSTP1, APC, and MDR1. This was done using the quantitative methylation-
specific PCR method. Therefore, the obtained results were correlated with 
the clinicopathologic findings. 
Results Promoter methylation of GSTP1 gene in voided urine samples was 
found in 87 out of 89 (97.8%) PCa patients and in 13 out of 62 (21 %) BPH 
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men. In APC gene, methylated levels have been found in 61 out of 89 
(68.5%) PCa patients and in 8 out of 62 (12.9%) BPH men. MDR1 gene was 
found to be hypermethylated in 60 out of 89 (67.4%) PCa patients and in 4 
out of 62 (6.5%) BPH men. In addition, we obtained a sensitivity of 88.99% 
and a specificity of 85.5% for the multigene panel. The AUC in this case was 
0.927. 
Conclusion  The analysis of a multigene panel of three methylated genes in 
prostate cancer by qMSP, can be used to distinguish between men with 
malignant and benign prostatic diseases from voided urine specimens. Also, 
it can be used for the follow-up of those men who are presenting increased 
risk of prostate cancer by noninvasive methods. 
 
Keywords: Prostate cancer (PCa), benign prostatic hyperplasia (BPH), 
quantitative  methylation-specific polymerase chain reaction (qMS-PCR), 
glutathione S-transferase P1 (GSTP1), multidrug resistance 1 (MDR1) gene, 
adenomatous polyposis coli (APC) gene 
 
Introduction 
 Worldwide, prostate cancer (PCa) represents the second leading 
cause of mortality in men. Each year, it is responsible for more than 29.000 
deaths (Siegel et al., 2013). However, this was because in its early stage, it 
evolves as asymptomatic. Generally, it is discovered in a late stage. 
Therefore, there is an urgent need for its introduction in the clinic of an 
algorithm. These include several sensitive biomarkers which can detect the 
disease at its early stage, by noninvasive techniques from body fluids. 
 Currently, the diagnostic of prostate cancer is done based on a 
combination between serum (PSA), digital rectal examination (DRE), and 
histological examination of transrectal ultrasound (TRUS)-guided biopsy. 
Since the introduction of serum prostate specific antigen (PSA) as a routine 
biomarker, in addition to the DRE, it has led to the increase of organ 
confined prostate cancer cases (Brawer, 2000). The use of serum PSA as a 
predictive biomarker in prostate cancer has some limitations. These 
limitations include low specificity of serum PSA which leads to frequent 
unnecessary sextant biopsies. In patients with the serum PSA levels in the 
range of 3 ng/ml and 10 ng/ml, known as the grey zone, the serum PSA test 
has low specificity to detect prostate cancer. Thus, this results in an increased 
rate of negative biopsies between 60% to 75%; hence, this will undergo 
unnecessary sextant biopsies (Schroder  et al., 2014). The increased levels of 
serum PSA above 3.00 ng/ml are considered to be associated with prostate 
cancer, while the increased levels of serum PSA are also present in benign 
prostatic diseases such as benign prostatic hyperplasia (BPH), which is 
observed in elderly (Thompson et al., 2004). Also, another inconvenience is 
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due to the TRUS-biopsies which can miss some tumoral foci or the presence 
of higher-grade tumor (Haffner et al., 2015). In the last twenty years, due to 
the developments in the field of molecular genetics, many genetic and 
epigenetic alterations have been discovered to be involved at the molecular 
level in the prostatic carcinogenesis. DNA methylation represents an 
important epigenetic modification which occurs during the process of 
carcinogenesis. Also, it involves the transfer of a methyl group to the 5’ 
position of the cytosine ring of the cytosine phosphate guanosine (CpG) 
dinucleotides through the DNA methyltransferases. DNA hypermethylation 
has been associated with carcinogenesis. In addition, some studies have 
shown that it occurs at the early stages of the carcinogenesis, making it an 
ideal biomarker for early cancer detection (Chiam et al., 2012). Although 
previous studies have shown that some methylated loci such as GSTP1, 
RASSF1A, and PTGS2 can be used as biomarkers for diagnostic and/or 
prognostic in prostate cancer (Roupret et al., 2007), recent studies have 
suggested that using methylated gene panels for the diagnosis and/or 
prognosis of prostate cancer patients can improve the sensibility and 
specificity of the test compared to serum PSA. However, this fact is 
important in deciding the need for a second prostate biopsy in patients with a 
first negative biopsy (Partin et al., 2014; Stewart et al., 2013). 
 In the present study, we would demonstrate that the use of a panel of 
3 methylated biomarkers (glutathione S-transferase P1 (GSTP1), 
adenomatous polyposis coli (APC), and multidrug resistance 1 (MDR1) can 
serve as an adjunct to serum PSA in the early diagnostic of prostate cancer. 
Subsequently, it can improve in distinguishing between malignant and 
benign lesions by noninvasive methods.  
 
Materials and Methods 
Patients, Sample Collection, and DNA Extraction 
 In our study, we included a number of 89 men with clinically 
localized prostate adenocarcinoma. They were primarily treated with radical 
prostatectomy at the Department of Urology from “Pius Brinzeu” Clinical 
Emergency Hospital in Timisoara, Romania. Thus, this took place between 
2014-2015. The cases were identified due to the increased levels of serum 
prostate specific antigen during routine analysis, and were confirmed by 
sextant prostate biopsy. All the biopsies were performed transrectally under 
ultrasound guidance. Also, a number of 62 men were included as controls in 
our study. They were confirmed by serum PSA levels in the range of 3.0 
ng/ml to 9.9 ng/ml, and it has an initial negative prostate biopsy result. In the 
control groups, men with no history of genitourinary malignancy were 
included. 
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 The eligibility criteria for prostate cancer patients’ selection were as 
follows: 
1. Only patients with clinical tumor stage I or II were included in the 
study. 
2. Only patients who had no clinical evidence of lymph node 
involvement or distant metastasis were included. 
3. Only patients who had no previous treatment with hormonal therapy 
or radiation therapy before urine sample collection were included. 
For the controls, the eligibility criteria were as follows: 
1. Serum PSA levels between 3.0 ng/ml and 9.9 ng/ml. 
2. A negative prostate biopsy result. 
 
Urine Sample Collection 
 The urine samples (20-30 mL) were collected following a digital 
rectal examination (DRE) which consisted of 3 strokes per prostatic lobe. 
Therefore, this was performed by the urologist. After the urine specimens 
were obtained, they were stored at 2–8 C and were processed within 4 hours. 
The urine samples were processed according to the procedures for the whole 
urine as described by Groskopf et al. (2006). On the other hand, the urine 
samples were processed for urinary sediments as described by Hessels et al. 
(2003). 
 In measuring the levels of serum PSA in the subjects included in our 
study, we used the enzyme linked-immunosorbent assay (ELISA) method. 
Thus, the measurements were done using an Advia Centaur immunoassay 
system (Bayer Healthcare, USA). 
 
Genomic DNA Extraction from Urine Samples 
 Consequently, we extracted the genomic DNA from urine samples 
using the Urine DNA Isolation Kit (Norgen, Biotek Corporation, Canada). 
After extraction, we quantified the obtained genomic DNA by measuring it 
with a Qubit 3.0 Fluorometer (Invitrogen, USA). 
 
Bisulfite Modification  
 Extracted DNA samples were subjected to sodium bisulfite 
conversion using the EpiTect Fast Bisulfite Conversion  Kit (Qiagen, 
Germany) by following the manufacturer’s instructions.  
 
Methylation Analysis 
 We used the bisulfite-treated DNA  as a template for the quantitative 
fluorescence  real-time methylation-specific PCR (qMSP) as it was 
previously described by Hoque (Hoque et al., 2007). We investigated the 
abberant promoter methylation using qMSP for three gene promoter regions: 
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GSTP1, MDR1, and APC. For the methyl quantification, the polymerase 
chain reaction was done using the bisulfite specific primers to the β-actin 
gene. The primers and probes have been designed using the MethyPrime Soft 
to amplify the bisulfite converted promoter of the genes. Fluorescence based 
real-time PCR assay was carried out in a reaction volume of 25 µL 
consisting of 0.25µL of each primer, 12.5 µL qPCR Master Mix (Fermentas, 
Lithuania), 2 µL bisulfite converted DNA, 0.5 µL of each sample, and 5 µL 
of distilled water. However, each sample was run in duplicate. As a positive 
control, we used universally methylated DNA (Chemicon, USA). All 
amplifications were carried out in a 96-well plates (Applied Biosystems, 
USA) on a 7500 Real -Time PCR System (Applied Biosystems, USA). The 
conditions for the amplification were as follows: 95° C for 10 minutes 
followed by 45 cycles of 95° C for 15 minutes, and 60° C for 1 minute.  
 
Ethical Aspects regarding the Study 
 The Institutional Committee of Ethics from Victor Babes University 
of Medicine and Pharmacy in Timisoara, Romania, approved our study. 
Therefore, it was carried out in  accordance with the World Medical 
Association Declaration of Helsinki for Human Research statements revised 
in 2013. First, we informed the subjects included in the study regarding the 
protocol of the study. After their acceptance to be part of the study, they gave 
their written informed consent. 
 
Statistical Analysis 
 The correlations between the methylation levels and the 
clinicopathological variables were evaluated using the nonparametric Mann-
Whitney tests for continous variables. 
 To discriminate malignant versus benign cells, we used the variables 
such as sensitivity and specificity of methylation. Consequently, this variable 
were determined by the receiver operator curve (ROC) analysis. The 
discriminatory power of the test was given by the area under the curve 
(AUC). 
 In determining the sensitivity and specificity of the DNA methylation 
in differentiating between the two groups, we calculated the receiver 
operating curve (ROC). Furthermore, we used Pearson’s correlation to 
evaluate the relation between methylation level of GSTP1, APC, and MDR1 
gene with the clinico-pathological parameters. 
 Statistical analysis were performed using SPSS ver. 20.0 (SPSS 
Inc.,Chicago,IL,USA). Also, we considered a p-value < 0.05 to be 
statistically significant. 
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Results 
 The baseline characteristics of the patients included in our study is 
presented in Table 1. In addition, the distribution between the methylated 
and unmethylated genes is presented in Figure 1. 
Table 1.  Characteristics of the prostate cancer cases and control cases included in the 
study 
Variables Sample N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Minimum Maximum 
AGE 
PROSTATE 
CANCER 
89 63.82 11.833 1.254 40 85 
CONTROL 62 58.74 15.034 1.909 25 88 
PSA 
PROSTATE 
CANCER 
89 17.27 5.497 0.583 10 35 
CONTROL 62 6.00 2.188 0.278 2 10 
 
Figure 1.  Distribution between methylated and unmethylated genes 
 
 
 However, we made correlations between different parameters and the 
methylation levels of  the three genes as follows: 
a. Correlations between methylation levels, preoperative serum 
prostate-specific antigen (PSA) levels, and age 
Preoperative serum PSA levels were increased in prostate cancer 
patients compared to those with benign prostatic hyperlasia (Mann-
Whitney test; p=0.028,α=0.05). 
Also, according to the Spearman rank-correlation test, there was a 
significant correlation between the serum PSA levels and the 
methylation levels of the three genes in the prostate cancer group 
(Spearman coefficient=0.872; p< 0.001). 
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b. Correlations between methylation levels of GSTP1, APC, and 
MDR1 in prostate cancer patients versus controls 
The methylation levels of gluthatione S-transferase P1 gene was 
significantly increased in the prostate cancer group when compared 
to the benign prostatic hyperplasia group (χ2 test ; p< 0.001). 
Glutathione S-transferase P1 gene was found hypermethylated in 87 
out of 89 (97.8%) patients with prostate cancer, and in 13 out of 69 
(21%) of those with benign prostatic hyperplasia. Using the receiver 
operating curve (ROC), we found that GSTP1 gene can discriminate 
between the prostate cancer patients and BPH patients. This is with a 
sensitivity of 87.75% and a specificity of 79.03%, respectively. The 
area under the curve (AUC) of the GSTP1 gene was 0.915. Thus, the 
AUC is presented in Figure 2 below. 
Figure 2. Receiver operating curve (ROC) analysis of GSTP1 gene hypermethylation 
levels in prostate cancer cases 
 
 
Adenomatous polyposis coli (APC) was found methylated in 61 out 
of 89 (68.5%) prostate cancer patients and in 8 out of 69 (12.9%) 
controls. The ROC in the case of APC gene presented a sensitivity of 
68.54% and a specificity of 87.1% in discriminating PCa from 
controls. The AUC was 0.771. Thus, the AUC is presented in Figure 
3 below. 
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Figure 3. Receiver operating curve (ROC) analysis of APC gene hypermethylation 
levels in prostate cancer cases 
 
Multidrug resistance 1 (MDR1) was found hypermethylated in 60 out 
of 89 (67.4%) prostate cancer patients and in 4 out of 62 (6.5%) 
controls. The receiver operating curve had a sensitivity of 67.42% 
and a specificity of 93.55%, respectively. The area under the curve 
(AUC) was 0.802. Hence, the AUC is presented in Figure 4 below. 
Figure 4. Receiver operating curve (ROC) analysis of MRD1 gene hypermethylation 
levels in prostate cancer cases 
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Figure 5. Multigene analysis of GSTP1, APC, and MDR1 genes 
 
The multigene panel has a sensitivity of 88.89 % and a specificity of 
85.5%, respectively. The area under the curve (AUC) in this case was 
0.927. 
 
Conclusion 
 Currently, the combination between serum PSA and DRE represents 
the most used methods for the clinicians for identifying those patients who 
present the risk of developing prostate cancer. The serum PSA test presents a 
sensitivity and specificity between 70% to 90% and 20% to 40%, 
respectively (Brawer, 1999). Brawer et al, in their study, obtained an area 
under the curve (AUC) in a range between 0.55 to 0.70. This was based on 
the ability of serum PSA to identify those men who present prostate cancer. 
Due to these disadvantages, there is an urgent need for validating new 
biomarkers which can aid in early detection.  
 However, regarding the development and progression of prostate 
carcinogenesis, many studies have been done related to the involvement of 
the DNA methylation (Goering et al., 2012). Glutathione S-transferase P1 
(GSTP1) gene promoter hypermethylation has been reported to be the most 
frequent epigenetic modification which occurs during prostate 
carcinogenesis. At present, it occurs in about 70% of high-grade prostatic 
intraepithelial neoplasia (HGPIN) lesions and in about 90% of neoplastic 
tissues samples when compared to normal benign tissue (Nakayama et al., 
2003). 
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 The study of Roupret et al. (2007) shows that using an epigenetic 
multigene panel made of 4 genes (GSTP1, RASSF1A, RARβ2, and APC), 
we demonstrated that this model could differentiate between malignant and 
nonmalignant cases with a sensitivity of 86% and a specificity of 89 %, 
respectively.  Consequently, Hoque et al examined the promoter methylation 
in 9 genes from urine sediment to distinguish between prostate cancer 
patients and control cases. Their results are correlated with the methylation 
levels from the corresponding primary tumors. From the panel of 9 genes, a 
combination of only 4 genes (p16, ARF, MGMT, and GSTP1) could detect 
prostate cancer with a sensitivity of 87% and a specificity of 100% (Hoque et 
al., 2005). 
 In our study, we determined the methylation levels of three 
methylated genes from urine samples: GSTP1, APC, and MRD1. Using the 
receiver operating curve (ROC), we found that each  gene can discriminate 
between the prostate cancer patients and BPH patients based on the obtained 
sensitivity and specificity for each. Moreover, in this study, we performed a 
methylation analysis of the combination of the three genes. In addition, we 
obtained a sensitivity of 88.9% and a specificity of 85.5%, respectively.  
 The obtained AUC for the multigene panel was 0.927. The 
limitations of our study can be represented by the small number of patients 
included in the study and the short period of time for the study. Therefore, 
further studies of larger study groups are needed to confirm our preliminary 
data. 
 In the future, this panel of methylated genes can be used for the early 
diagnosis of prostate cancer by noninvasive methods. Therefore, its aim is to 
reduce the need for repeated prostate biopsy, and to follow-up men that 
shows higher risk of prostate cancer. 
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